Klaviyo Q3 2026 Earnings: Key Metrics Awaited Amid Growth and AI Scrutiny

What happened

Klaviyo reported fiscal Q3 2026 results, and a Zacks article notes that while top- and bottom-line numbers are out, investors should focus on key metrics versus estimates and year-ago values. The article does not provide specific figures, leaving the market to review the company's commentary and metrics such as net revenue retention (NRR), customer additions above $50K ARR, and revenue growth consistency with the FY26 guidance range of $1.514B–$1.522B. The latest 10-Q (Q1 FY26) had set expectations for NRR to hold at or above 110% and for Q2 revenue to land within $359M–$363M, but Q3 data are not yet disclosed in the article. Prior analysis flagged near-term checkpoints including ASR final settlement, repurchase pace after the 10b5-1 plan expiration, and AI regulatory compliance costs, none of which are addressed in the brief news item. Without concrete metrics, the company's ability to sustain low-20% growth and operating leverage while funding buybacks remains the central question, and the current stock price around $14.60 already embeds skepticism about a durable re-rating.

Implication

Investors should treat the Q3 release as an interim checkpoint rather than a decisive event given the lack of detail in the news article. The critical data points are NRR relative to the 110% baseline, growth in >$50K ARR customers, and any commentary on AI compliance expenses that could pressure the 14.5%–15.0% non-GAAP margin guide. Buyback execution net of dilution remains a key swing factor, especially after the ASR settlement and the 10b5-1 plan's expiration; a slowdown would undermine the per-share compounding thesis. Until those figures are confirmed, the stock is likely to remain rangebound between $12 and $17, with downside risk if NRR breaks below 105% or guidance is cut. Upside requires evidence that agentic AI features are monetizing and that operating leverage is durable.

Thesis delta

No change to the base thesis that KVYO is an autonomous B2C CRM with a balance-sheet margin of safety but limited earnings support at $14.60. The Q3 earnings release, as summarized by Zacks, does not yet provide the verification needed on NRR or buyback pace, leaving the risk/reward balanced. The thesis will strengthen if detailed metrics confirm NRR ≥110% and share count reduction; it will weaken if AI compliance costs erode margins or growth decelerates below guidance.